Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
NASDAQ:GILD
Price:
67.01 USD
-0.95%
Market Closed
Updated:
May 16, 2024
Gilead Sciences Inc
Pre-Tax Income
|
Gilead Sciences Inc
Pre-Tax Income Peer Comparison
Comparables:
ABBV
AMGN
MRNA
VRTX
REGN
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$1.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-16%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Pre-Tax Income
-$4.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
See Also
What is Gilead Sciences Inc's Pre-Tax Income?
Pre-Tax Income
1.1B
USD
1.1B
USD
Based on the financial report for Mar 31, 2024, Gilead Sciences Inc's Pre-Tax Income amounts to 1.1B USD.
What is Gilead Sciences Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-16%
-16%
Over the last year, the Pre-Tax Income growth was -85%. The average annual Pre-Tax Income growth rates for Gilead Sciences Inc have been -18% over the past three years , -33% over the past five years , and -16% over the past ten years .
You don't have any saved screeners yet
